Torrisi R, Parodi S, Fontana V, Rondanina G, Formelli F, Costa A, Boccardo F, Decensi A
Department of Medical Oncology II, National Institute for Cancer, Genoa, Italy.
Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):507-10.
Administration of the synthetic retinoid Fenretinide lowers circulating retinol and may thus affect night vision. We have recently shown that plasma retinol levels below 100 ng/ml are associated with moderate alterations of the dark adaptometry test. To identify which patients are more likely to experience a decrease of plasma retinol under this threshold, we measured plasma levels of retinol, Fenretinide, and its metabolite 4-MPR in a cohort of 28 women receiving Fenretinide at the daily dose of 200 mg and studied their relationship with clinical characteristics such as age, menstrual status, body mass index, and time on treatment. Our results show that patients aged over 55 years with a higher percentage of adipose tissue had higher plasma concentrations of 4-MPR, which turned out to be the major determinant of the retinol decrease. This subgroup may thus deserve careful ophthalmological surveillance.
合成视黄酸芬维A胺的给药会降低循环视黄醇水平，因此可能会影响夜间视力。我们最近发现，血浆视黄醇水平低于100 ng/ml与暗适应测量试验的中度改变有关。为了确定哪些患者在该阈值以下更有可能出现血浆视黄醇降低，我们在一组28名每日接受200 mg芬维A胺治疗的女性中测量了视黄醇、芬维A胺及其代谢物4-MPR的血浆水平，并研究了它们与年龄、月经状态、体重指数和治疗时间等临床特征的关系。我们的结果表明，年龄超过55岁且脂肪组织百分比更高的患者血浆4-MPR浓度更高，而这被证明是视黄醇降低的主要决定因素。因此，这一亚组患者可能值得进行仔细的眼科监测。
